CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is trending Thursday, up more than 45% over the past month. Here’s a look at what’s driving the move. What To Know: In late June, the company reported new ...

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

CRISPR Therapeutics AG (NASDAQ:CRSP) in Cathie Wood’s Stock Portfolio is one of the top 10 stocks to buy now. On August 7, analysts at H.C. Wainwright reiterated a ‘Buy’ rating on the stock and raised ...

CRISPR Therapeutics (CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common shares through Jefferies LLC, acting as its sales agent.

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...